May 6, 2020· Comment from Association for Accessible Medicines (AAM)· FDA-2020-N-0437-0006
The Association for Accessible Medicines (AAM), and its Biosimilars Council (collectively referred to in these comments as AAM), are pleased to submit written comments to the docket "Purple Book Enhancement; Establishment of a Public Docket; Request for Comments." AAM applauds the Agency's update to the Purple Book. This effort will create a single searchable electronic database that identifies each biosimilar and interchangeable biologic with its reference product. Please find our full comments enclosed.